- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Influenza A
- Influenza B
- Pharmacological intervention
- Immunomodulator
- PRS CK STORM
Intervention: Pharmacological intervention
This refers to the drug, therapy, or factor being studied in a clinical trial or observational study. Examples include antiviral agents monoclonal antibodies, corticosteroids, vaccines and other pharmacological agents
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Remdesivir
- Tixagevimab/Cilgavimab
- Hydroxychloroquine
- Interferon Beta-1A
- Lopinavir/ritonavir
- Adults (18-64 years)
- Elderly (≥65 years)
- Immunocompromised patients
- Hospital
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Adenovirus
- Rhinovirus
- Human metapneumovirus
- Parainfluenza Virus
- Pharmacological intervention
- Antivirals
- SNG001
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Vaccination
- Nasal vaccine
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Apo-Si-K170A-C76
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Influenza virus
- Streptococcus pneumoniae
- Influenza-like illness/Acute respiratory infection
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Primary care
- Influenza-like illness/Acute respiratory infection
- Pharmacological intervention
- Telehealth
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab